Lophora ApS

Lophora is a preclinical biotech company. The company has identified and patented a new class of proprietary compounds with a similar pharmacological profile to psilocybin, which has shown promising clinical results in treating a variety of conditions such as depression and addiction.

The company is currently bringing its first-in-class lead molecule LPH-5 through pre-clinical toxicological evaluation and expects to be ready for the initiation of clinical trials by 2024.

Based on +10 years of research from the University of Copenhagen, Lophora was founded in 2018 with the ambition of developing a novel class of proprietary small molecules with a unique selectivity profile to address conditions with significant unmet need such as Treatment-Resistant Depression, whose patients remain largely underserved.

Contact name:

Bo Tandrup


Gyldenlundsvej 21, 1, 2920 Charlottenlund


+45 51 86 84 82



Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact ps@danskbiotek.dk or +45 7172 1114

Copyright 2021 DANISH BIO – DANSK BIOTEK. All rights reserved.